journal article·2026-06

Metabolic microenvironment-forming porous hydrogels for the protection of phenylalanine ammonia-lyase in the intestine

Sofie Dhondt, Philippe Delbreil, Shihao Pei, Catherine Nadeau, Inès Kadi, Isabelle Masseau, Fatma Moawad, Xavier Banquy, Davide Brambilla

Biomaterials· Volume 329
Publisher page

Abstract

Biological therapeutics drive biomedical innovation, yet their oral delivery is hindered by gastrointestinal instability. Phenylalanine ammonia-lyase (PAL), a promising enzyme for phenylketonuria management, exemplifies this challenge. Here, we present ultraporous template-based hydrogels (TGels) that protect and deliver PAL in the small intestine. PAL-TGels are obtained via UV crosslinking of poly(ethylene glycol) diacrylamide in the presence of sacrificial CaCO3 templates, followed by absorption-based loading of PAL and a protease inhibitor. The interconnected porous matrix retains PAL while allowing phenylalanine and trans-cinnamic acid diffusion for continuous catalysis. In vitro studies confirmed robust protein retention and preserved enzymatic activity in simulated intestinal fluid, without impairing global trypsin function, while large animal tests validated matrix properties and transit. This fabrication-efficient platform enables localized intestinal enzyme protection, offering a promising route toward safe and accessible oral PAL therapy for phenylketonuria.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Hydrogels: synthesis, properties, applications · Metabolism and Genetic Disorders · Enzyme Catalysis and Immobilization

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (83)

Show source-provided references
1. THPdb2: compilation of FDA approved therapeutic peptides and proteins10.1016/j.drudis.2024.104047 ↗
2. Physicochemical factors of bioprocessing impact the stability of therapeutic proteins10.1016/j.biotechadv.2022.107909 ↗
3. Instability challenges and stabilization strategies of pharmaceutical proteins10.3390/pharmaceutics14112533 ↗
4. Targeting of gastrointestinal tract for amended delivery of protein/peptide therapeutics: strategies and industrial perspectives10.1016/j.jconrel.2014.09.031 ↗
5. Oral delivery of biologics via the intestine10.3390/pharmaceutics13010018 ↗
6. Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs10.1021/mp500809f ↗
7. Oral peptide delivery: translational challenges due to physiological effects10.1016/j.jconrel.2018.08.032 ↗
8. 2025
9. Biochemical and structural analysis of substrate specificity of a phenylalanine ammonia-lyase10.1104/pp.17.01608 ↗
11. The genetic landscape and epidemiology of Phenylketonuria10.1016/j.ajhg.2020.06.006 ↗
12. National institutes of health consensus development conference statement: phenylketonuria: screening and management, October 16–18, 200010.1542/peds.108.4.972 ↗
14. 2017
15. Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial10.1186/s13023-021-01968-1 ↗
16. Effects of oral sepiapterin on blood phe concentration in a broad range of patients with phenylketonuria (APHENITY): results of an international, phase 3, randomised, double-blind, placebo-controlled trial10.1016/S0140-6736(24)01556-3 ↗
17. Sepiapterin: a potential new therapy for phenylketonuria10.1016/S0140-6736(24)01819-1 ↗
18. P047: interim results from the APHENITY extension study: sepiapterin reduces blood Phe with improved dietary Phe tolerance in participants with phenylketonuria10.1016/j.gimo.2025.102891 ↗
19. Pegvaliase: first global approval10.1007/s40259-018-0292-3 ↗
20. The influence of phenylalanine intake on phenylketonuria10.1016/S0140-6736(53)90473-5 ↗
21. Phenylketonuria as an adherence disease10.2147/PPA.S512719 ↗
22. Current advances and material innovations in the search for novel treatments of Phenylketonuria10.1002/adhm.202401353 ↗
23. A new theory of enterorecirculation of amino acids and its use for depleting unwanted amino acids using oral enzyme-artificial cells, as in removing phenylalanine in Phenylketonuria, artificial cells, blood substitutes
24. Phenylalanine ammonia-lyase immobilized in semipermeable microcapsules for enzyme replacement in phenylketonuria10.1016/0014-5793(85)80219-2 ↗
25. Entrapment of phenylalanine ammonia-lyase in silk fibroin for protection from proteolytic attack10.1016/S0006-291X(86)80349-7 ↗
26. A silk-based platform to stabilize phenylalanine ammonia-lyase for orally administered enzyme replacement therapy10.1021/acs.molpharmaceut.2c00512 ↗
27. Enzyme shielding in a large mesoporous hollow Silica Shell for improved recycling and stability based on CaCO3 microtemplates and biomimetic silicification10.1021/acs.jafc.7b00672 ↗
28. Mesoporous phenylalanine ammonia lyase microspheres with improved stability through calcium carbonate templating10.1016/j.ijbiomac.2017.02.059 ↗
29. Encapsulation of spherical cross-linked phenylalanine ammonia lyase aggregates in mesoporous Biosilica10.1021/acs.jafc.6b05003 ↗
30. Converting an injectable protein therapeutic into an oral form: phenylalanine ammonia lyase for phenylketonuria10.1016/j.ymgme.2009.09.002 ↗
31. A microparticulate based formulation to protect therapeutic enzymes from proteolytic digestion: phenylalanine ammonia lyase as case study10.1038/s41598-020-60463-y ↗
32. Paper-based biosensor based on phenylalnine ammonia lyase hybrid nanoflowers for urinary phenylalanine measurement10.1016/j.ijbiomac.2020.10.218 ↗
33. Biomedical applications of functional hydrogels: innovative developments, relevant clinical trials and advanced products10.1016/j.biomaterials.2024.122718 ↗
34. A comprehensive review of Hydrogel-based drug delivery systems: classification, properties, recent trends, and applications10.1208/s12249-024-02786-x ↗
35. In vitro evaluation of the gastrointestinal delivery of acid-sensitive pancrelipase in a next generation enteric capsule using an exocrine pancreatic insufficiency disease model10.1016/j.ijpharm.2022.122441 ↗
36. In vivo evaluation of a gastro-resistant enprotect® capsule under postprandial conditions10.3390/pharmaceutics15112576 ↗
37. In vivo evaluation of a gastro-resistant HPMC-based “Next Generation Enteric” capsule10.3390/pharmaceutics14101999 ↗
38. Template-based porous hydrogel microparticles as carriers for therapeutic proteins10.1021/acsbiomedchemau.3c00001 ↗
39. Anti-erosive effect of calcium carbonate suspensions
40. Superswelling microneedle arrays for dermal interstitial fluid (Prote)Omics10.1002/adfm.202106061 ↗
41. A naked eye-invisible ratiometric fluorescent microneedle tattoo for real-time monitoring of inflammatory skin conditions10.1002/adhm.202102070 ↗
42. Rational design of a new class of versatile enzyme-based biosensors10.1021/acs.analchem.4c06519 ↗
43. A microwave-assisted method for the synthesis of symmetrical and unsymmetrical cyanine dyes10.1021/acs.joc.4c02539 ↗
44. The Bowman-Birk inhibitor. Trypsin- and chymotrypsin-inhibitor from soybeans10.1111/j.1399-3011.1985.tb02155.x ↗
45. UCSF Chimera--a visualization system for exploratory research and analysis10.1002/jcc.20084 ↗
46. Highly accurate protein structure prediction with AlphaFold10.1038/s41586-021-03819-2 ↗
47. Native PAGE eliminates the problem of PEG-SDS interaction in SDS-PAGE and provides an alternative to HPLC in characterization of protein PEGylation10.1002/elps.200600807 ↗
48. Fabrication and characterization of porous PEGDA hydrogels for articular cartilage regeneration10.3390/gels10070422 ↗
49. Molecular aspects of mucoadhesive carrier development for drug delivery and improved absorption10.1163/156856208X393464 ↗
50. Tailoring the swelling-shrinkable behavior of hydrogels for biomedical applications
51. Investigation of the swelling behavior of hydrogels derived from high-molecular-weight poly(2-ethyl-2-oxazoline)10.1002/pol.20190267 ↗
52. Torpac Inc, Capsule size chart, (n.d.). https://www.torpac.com/Reference/Torpac%20Size%20Chart.pdf (accessed July 3, 2025).
53. Gastro intestinal tracking and gastric emptying of solid dosage forms in rats using X-ray imagining10.1016/j.ijpharm.2010.01.001 ↗
54. The value of barium as a gastrointestinal contrast agent in MR imaging: a comparison study in normal volunteers10.2214/ajr.157.4.1892032 ↗
55. Colonic delivery of aqueous suspensions using 3D printed capsules10.1002/admt.202301975 ↗
56. Changes in the mechanical properties of alginate-gelatin hydrogels with the addition of Pygeum africanum with potential application in urology10.3390/ijms231810324 ↗
57. Theranostic gastrointestinal residence systems10.1016/j.device.2023.100053 ↗
58. Additive manufacturing and physicomechanical characteristics of PEGDA hydrogels: recent advances and perspective for tissue engineering10.3390/polym15102341 ↗
59. USP, the Dissolution Procedure - Development and Validation <1092>, in: USP-NF, Rockville, MD, n.d.
60. How to assess regional and whole gut transit time with wireless motility capsule10.5056/jnm.2014.20.2.265 ↗
61. Swelling of high acyl gellan gum hydrogel: characterization of network strengthening and slower release10.1016/j.carbpol.2021.117758 ↗
62. Structural characterization and developability assessment of sustained release hydrogels for rapid implementation during preclinical studies10.1016/j.ejps.2020.105689 ↗
63. Influence of PEGDA molecular weight and concentration on the in vitro release of the model protein BSA–FITC from photo crosslinked systems10.3390/pharmaceutics15041039 ↗
64. Long-term controlled protein release from Poly(Ethylene glycol) hydrogels by modulating mesh size and degradation10.1002/mabi.201500245 ↗
65. Effects of PEG hydrogel crosslinking density on protein diffusion and encapsulated islet survival and function10.1002/jbm.a.32134 ↗
66. A multiscale model for solute diffusion in hydrogels10.1021/acs.macromol.9b00753 ↗
67. Adsorption and sustained delivery of small molecules from nanosilicate hydrogel composites10.3390/ph15010056 ↗
68. Diffusion-limited processes in hydrogels with chosen applications from drug delivery to electronic components10.3390/molecules28155931 ↗
69. Stabilization of proteins in solid form10.1016/j.addr.2015.05.006 ↗
70. How sugars protect dry protein structure10.1021/acs.biochem.2c00692 ↗
71. How sugars protect proteins in the solid state and during drying (review): mechanisms of stabilization in relation to stress conditions10.1016/j.ejpb.2017.01.024 ↗
72. Extraordinary stability of enzymes dried in trehalose: simplified molecular biology
73. Reagents, Simulated intestinal fluid TS, in: United States Pharmacopeia, USP-NF, Rockville, MD, n.d. https://doi.usp.org/USPNF/USPNF_XR3188_01_01.html (accessed September 7, 2025).
74. Noncovalent PEGylation of protein and peptide therapeutics10.1002/wnan.1897 ↗
75. How PEGylation influences protein conformational stability10.1016/j.cbpa.2016.08.006 ↗
76. PEGylated human serum albumin: review of PEGylation, purification and characterization methods10.15171/apb.2016.043 ↗
77. Formulation and PEGylation optimization of the therapeutic PEGylated phenylalanine ammonia lyase for the treatment of phenylketonuria10.1371/journal.pone.0173269 ↗
78. Aprotinin and similar protease inhibitors as drugs against influenza10.1016/j.antiviral.2011.07.014 ↗
79. Multidimensional analysis of human intestinal fluid composition10.1016/j.ejpb.2020.06.011 ↗
80. Covalent incorporation of Trehalose within hydrogels for enhanced long-term functional stability and controlled release of biomacromolecules10.1002/adhm.201500334 ↗
81. Trehalose glycopolymers as excipients for protein stabilization10.1021/bm4003046 ↗
82. Protein–hydrogel interactions in tissue engineering: mechanisms and applications10.1089/ten.teb.2012.0458 ↗
83. Acidification of phosphate buffered saline10.1016/j.ijpharm.2025.125593 ↗